

Surface Protein Therapeutic Pipeline Market Review, H2 2016

Surface Protein Treatment Pipeline Review H2 2016

PUNE, INDIA, October 5, 2016

/EINPresswire.com/ -- '[Surface Protein](#) gp120 - Pipeline Review, H2 2016', provides in depth analysis on Surface Protein gp120 targeted pipeline therapeutics.

The report provides comprehensive information on the Surface Protein gp120, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Surface Protein gp120 targeted therapeutics development and features dormant and discontinued projects.

Complete Report @ <https://www.wiseguyreports.com/reports/668892-surface-protein-gp120-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.



Scope

- The report provides a snapshot of the global therapeutic landscape for Surface Protein gp120
- The report reviews Surface Protein gp120 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Surface Protein gp120 targeted therapeutics and enlists all their major and minor projects
- The report assesses Surface Protein gp120 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Surface Protein gp120 targeted therapeutics

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/668892-surface-protein-gp120-pipeline-review-h2-2016>

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Surface Protein gp120
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Surface Protein gp120 development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Have any query @ <https://www.wiseguyreports.com/enquiry/668892-surface-protein-gp120-pipeline-review-h2-2016>

Table of Contents

Table of Contents	2
List of Tables	6
List of Figures	6
Introduction	7
Global Markets Direct Report Coverage	7
Surface Protein gp120 Overview	8
Therapeutics Development	9
Surface Protein gp120 - Products under Development by Stage of Development	9
Surface Protein gp120 - Products under Development by Therapy Area	10
Surface Protein gp120 - Products under Development by Indication	11
Surface Protein gp120 - Pipeline Products Glance	12
Late Stage Products	12
Early Stage Products	13
Surface Protein gp120 - Products under Development by Companies	14
Surface Protein gp120 - Products under Development by Universities/Institutes	16
Surface Protein gp120 - Therapeutics Assessment	18
Assessment by Monotherapy/Combination Products	18
Assessment by Mechanism of Action	19
Assessment by Route of Administration	20
Assessment by Molecule Type	22
Surface Protein gp120 - Companies Involved in Therapeutics Development	24
GlaxoSmithKline Plc	24
Osel, Inc.	25
Sanofi Pasteur SA	26
TeneoBio Inc	27
United Biomedical, Inc.	28
ViiV Healthcare Limited	29
Surface Protein gp120 - Drug Profiles	30
Abzentek - Drug Profile	30
Product Description	30
Mechanism Of Action	30
R&D Progress	30
AIDSVAX B/B + ALVAC-HIV vCP1521 - Drug Profile	31
Product Description	31
Mechanism Of Action	31
R&D Progress	31
Biologic for Infectious Disease - Drug Profile	33
Product Description	33
Mechanism Of Action	33
R&D Progress	33
BMD-101 - Drug Profile	35
Product Description	35
Mechanism Of Action	35

R&D Progress 35
BMD-104 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
BMS-585248 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
DS-003 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
fostemsavir tromethamine - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
HIV [strains C1086 + TV1] (bivalent) vaccine - Drug Profile 42
Continued...

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=668892 □

Follow Us:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/347933762>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.